These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 19646795

  • 1. [Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting].
    Sicras-Mainar A, Blanca-Tamayo M, Gutiérrez-Nicuesa L, Salvatella-Pasant J, Navarro-Artieda R.
    Gac Sanit; 2010; 24(1):13-9. PubMed ID: 19646795
    [Abstract] [Full Text] [Related]

  • 2. Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences.
    Sicras-Mainar A, Navarro-Artieda R, Blanca-Tamayo M, Gimeno-de la Fuente V, Salvatella-Pasant J.
    Curr Med Res Opin; 2010 Dec; 26(12):2757-64. PubMed ID: 21034375
    [Abstract] [Full Text] [Related]

  • 3. [Costs and associated factors with optimal and suboptimal responses to the treatment of major depressive disorder].
    Sicras-Mainar A, Mauriño J, Cordero L, Blanca-Tamayo M, Navarro-Artieda R.
    Aten Primaria; 2012 Nov; 44(11):667-75. PubMed ID: 22789772
    [Abstract] [Full Text] [Related]

  • 4. Impact of non-remission of depression on costs and resource utilization: from the COmorbidities and symptoms of DEpression (CODE) study.
    Dennehy EB, Robinson RL, Stephenson JJ, Faries D, Grabner M, Palli SR, Stauffer VL, Marangell LB.
    Curr Med Res Opin; 2015 Jun; 31(6):1165-77. PubMed ID: 25879140
    [Abstract] [Full Text] [Related]

  • 5. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG, Fernández JL, François C, Hansen K, Danchenko N, Despiegel N.
    Pharmacoeconomics; 2008 Jun; 26(11):969-81. PubMed ID: 18850765
    [Abstract] [Full Text] [Related]

  • 6. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder.
    Schultz J, Joish V.
    Psychiatr Serv; 2009 Dec; 60(12):1604-11. PubMed ID: 19952150
    [Abstract] [Full Text] [Related]

  • 7. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.
    Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD.
    Curr Med Res Opin; 2010 Oct; 26(10):2475-84. PubMed ID: 20825269
    [Abstract] [Full Text] [Related]

  • 8. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G, Zhang L, DiBernardo A, Wang G, Sheehan JJ, Lee K, Reutfors J, Zhang Q.
    PLoS One; 2020 Oct; 15(9):e0238843. PubMed ID: 32915863
    [Abstract] [Full Text] [Related]

  • 9. [Incidence, resource use and costs associated with postherpetic neuralgia: a population-based retrospective study].
    Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J, Pérez-Ronco J.
    Rev Neurol; 2012 Oct 16; 55(8):449-61. PubMed ID: 23055426
    [Abstract] [Full Text] [Related]

  • 10. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ.
    CNS Drugs; 2008 Oct 16; 22(11):963-73. PubMed ID: 18840035
    [Abstract] [Full Text] [Related]

  • 11. The societal cost of depression: evidence from 10,000 Swedish patients in psychiatric care.
    Ekman M, Granström O, Omérov S, Jacob J, Landén M.
    J Affect Disord; 2013 Sep 25; 150(3):790-7. PubMed ID: 23611536
    [Abstract] [Full Text] [Related]

  • 12. Smoking Status and Cost of Illness in Patients with Depressive Disorder Based on the National Health Survey in Spain.
    López Ibáñez de Aldecoa A, Cedillo Gómez S, Bruguera E, García-Portilla MP, Bobes J.
    Subst Use Misuse; 2019 Sep 25; 54(5):713-723. PubMed ID: 30585110
    [Abstract] [Full Text] [Related]

  • 13. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom.
    Denee T, Ming T, Waller J, Bailey T, Rajkovic-Hooley O, Middleton-Dalby C, Le HH, Zhang Q, McCrone P, Taylor D.
    Curr Med Res Opin; 2021 Feb 25; 37(2):311-319. PubMed ID: 33253055
    [Abstract] [Full Text] [Related]

  • 14. The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.
    Rovira J, Albarracin G, Salvador L, Rejas J, Sánchez-Iriso E, Cabasés JM.
    Community Ment Health J; 2012 Jun 25; 48(3):372-83. PubMed ID: 22484993
    [Abstract] [Full Text] [Related]

  • 15. Prospective study of the use of healthcare resources and economic costs in patients with fibromyalgia after treatment in routine medical practice.
    Rivera J, Rejas-Gutiérrez J, Vallejo MA, Esteve-Vives J, De Salas-Cansado M, ICAF Group.
    Clin Exp Rheumatol; 2012 Jun 25; 30(6 Suppl 74):31-8. PubMed ID: 22935246
    [Abstract] [Full Text] [Related]

  • 16. Economic impact of treatment-resistant depression: A retrospective observational study.
    Pérez-Sola V, Roca M, Alonso J, Gabilondo A, Hernando T, Sicras-Mainar A, Sicras-Navarro A, Herrera B, Vieta E.
    J Affect Disord; 2021 Dec 01; 295():578-586. PubMed ID: 34509073
    [Abstract] [Full Text] [Related]

  • 17. Costs of depression in Catalonia (Spain).
    Salvador-Carulla L, Bendeck M, Fernández A, Alberti C, Sabes-Figuera R, Molina C, Knapp M.
    J Affect Disord; 2011 Jul 01; 132(1-2):130-8. PubMed ID: 21402411
    [Abstract] [Full Text] [Related]

  • 18. Economic impact of patients admitted to stroke units in Spain.
    Alvarez-Sabín J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, Becerra V, Torres C, Yebenes M, CONOCES Investigators Group.
    Eur J Health Econ; 2017 May 01; 18(4):449-458. PubMed ID: 27084749
    [Abstract] [Full Text] [Related]

  • 19. [Economic cost of treating the patient with asthma in Spain: the AsmaCost study].
    Martínez-Moragón E, Serra-Batllés J, De Diego A, Palop M, Casan P, Rubio-Terrés C, Pellicer C, por el Grupo de Investigadores del estudio AsmaCost.
    Arch Bronconeumol; 2009 Oct 01; 45(10):481-6. PubMed ID: 19525051
    [Abstract] [Full Text] [Related]

  • 20. Indirect and direct costs of acute coronary syndromes with comorbid atrial fibrillation, heart failure, or both.
    Ghushchyan V, Nair KV, Page RL.
    Vasc Health Risk Manag; 2015 Oct 01; 11():25-34. PubMed ID: 25565859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.